CG MedTech Co.,Ltd. (KOSDAQ:056090)
South Korea · Delayed Price · Currency is KRW 2,140.00
-115.00 (-5.10%)
At close: Apr 2, 2026
CG MedTech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 47,235 | 34,623 | 34,969 | 41,169 | 38,055 |
Other Revenue | - | -0 | -0 | -0 | - |
| 47,235 | 34,623 | 34,969 | 41,169 | 38,055 | |
Revenue Growth (YoY) | 36.43% | -0.99% | -15.06% | 8.18% | 37.01% |
Cost of Revenue | 26,372 | 18,834 | 17,139 | 22,518 | 22,571 |
Gross Profit | 20,863 | 15,789 | 17,829 | 18,651 | 15,484 |
Selling, General & Admin | 11,682 | 12,430 | 13,952 | 12,638 | 10,525 |
Research & Development | 3,759 | 3,357 | 4,462 | 4,471 | 4,893 |
Amortization of Goodwill & Intangibles | 311.4 | 86.48 | 97.52 | 106.96 | 137.85 |
Other Operating Expenses | 221.49 | 127.64 | 117.83 | 143.14 | 126.68 |
Operating Expenses | 17,060 | 16,885 | 15,626 | 28,828 | 16,299 |
Operating Income | 3,802 | -1,096 | 2,204 | -10,177 | -815.21 |
Interest Expense | -176.29 | -185.71 | -535.88 | -6,317 | -1,294 |
Interest & Investment Income | 474.32 | 571.87 | 374.56 | 592.34 | 102.16 |
Earnings From Equity Investments | - | 15.75 | - | - | - |
Currency Exchange Gain (Loss) | -50.89 | 691.8 | 148.54 | 382.6 | 490.54 |
Other Non Operating Income (Expenses) | 107.47 | 141.31 | -262.14 | -3,896 | -160.49 |
EBT Excluding Unusual Items | 4,157 | 138.85 | 1,929 | -19,416 | -1,677 |
Gain (Loss) on Sale of Investments | -1,421 | -258.52 | -340.46 | 672.25 | 191.93 |
Gain (Loss) on Sale of Assets | 172.92 | 132.53 | 261.96 | 165.77 | 23.41 |
Asset Writedown | -173.18 | - | -463.9 | - | -3,944 |
Other Unusual Items | - | - | - | 156.54 | - |
Pretax Income | 2,736 | 12.86 | 1,387 | -18,421 | -5,406 |
Income Tax Expense | -3,772 | 137.79 | 80.88 | 386.87 | -190.67 |
Earnings From Continuing Operations | 6,508 | -124.94 | 1,306 | -18,808 | -5,215 |
Minority Interest in Earnings | - | 184.63 | 323.44 | 268.83 | 244.37 |
Net Income | 6,508 | 59.69 | 1,629 | -18,540 | -4,970 |
Net Income to Common | 6,508 | 59.69 | 1,629 | -18,540 | -4,970 |
Net Income Growth | 10801.84% | -96.34% | - | - | - |
Shares Outstanding (Basic) | 103 | 60 | 79 | 67 | 45 |
Shares Outstanding (Diluted) | 103 | 60 | 79 | 67 | 45 |
Shares Change (YoY) | 73.05% | -24.33% | 18.55% | 49.47% | 16.01% |
EPS (Basic) | 63.00 | 1.00 | 20.65 | -278.64 | -111.66 |
EPS (Diluted) | 63.00 | 1.00 | 20.65 | -279.00 | -112.00 |
EPS Growth | 6200.00% | -95.16% | - | - | - |
Free Cash Flow | -8,866 | 736.7 | -4,068 | -6,184 | 375.08 |
Free Cash Flow Per Share | -85.84 | 12.34 | -51.58 | -92.95 | 8.43 |
Gross Margin | 44.17% | 45.60% | 50.99% | 45.30% | 40.69% |
Operating Margin | 8.05% | -3.17% | 6.30% | -24.72% | -2.14% |
Profit Margin | 13.78% | 0.17% | 4.66% | -45.03% | -13.06% |
Free Cash Flow Margin | -18.77% | 2.13% | -11.63% | -15.02% | 0.99% |
EBITDA | 6,066 | 596.09 | 4,057 | -7,977 | 1,347 |
EBITDA Margin | 12.84% | 1.72% | 11.60% | -19.38% | 3.54% |
D&A For EBITDA | 2,264 | 1,692 | 1,853 | 2,201 | 2,162 |
EBIT | 3,802 | -1,096 | 2,204 | -10,177 | -815.21 |
EBIT Margin | 8.05% | -3.17% | 6.30% | -24.72% | -2.14% |
Effective Tax Rate | - | 1071.82% | 5.83% | - | - |
Advertising Expenses | 59.82 | 85.15 | 351.37 | 311.16 | 176.3 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.